Current Report Filing (8-k)
June 14 2022 - 5:06PM
Edgar (US Regulatory)
0000318306
false
0000318306
2022-06-14
2022-06-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): June 14, 2022
ABEONA
THERAPEUTICS INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-15771 |
|
83-0221517 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
1330
Avenue of the Americas, 33rd Floor,
New
York, NY 10019
(Address
of principal executive offices) (Zip Code)
(646)
813-4712
(Registrant’s telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 par value |
|
ABEO |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07. | Submission
of Matters to a Vote of Security Holders. |
On
June 14, 2022, Abeona Therapeutics Inc. (the “Company”) held a special meeting of stockholders virtually at which the following
actions were taken (the “Special Meeting”). The proposals below are described in detail in the Company’s definitive
proxy statement for the Special Meeting dated May 12, 2022.
Proposal
1.
A
proposal to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common
stock at a ratio to be determined by the Board within a range of one-for-10 to one-for-80 (or any number in between), without reducing
the authorized number of shares of the Company’s common stock, to be effected in the sole discretion of the Board at any time within
one year of the date of the Special Meeting without further approval or authorization of stockholders, was approved based on the
following votes:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| 3,622,369,125 | | |
| 248,520,951 | | |
| 857,833 | | |
| — | |
Proposal
2.
The
proposal to approve any adjournment or postponement of the Special Meeting, if necessary, to solicit additional proxies if there were
insufficient votes at the time of the Special Meeting to approve Proposal No. 1 was approved based on the following votes:
Votes For | | |
Votes Against | | |
Abstentions | | |
Broker Non-Votes | |
| 112,736,819 | | |
| 8,071,465 | | |
| 864,625 | | |
| — | |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Abeona Therapeutics Inc. |
|
(Registrant) |
|
|
|
|
By: |
/s/
Joseph Vazzano |
|
Name: |
Joseph Vazzano |
|
Title: |
Chief Financial Officer |
Date:
June 14, 2022
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024